NPI: 1659856060 · WADESBORO, NC 28170 · General Acute Care Hospital · NPI assigned 10/02/2018
Authorized official DEFURIO, ANTHONY controls 19+ related entities in our dataset. Read more
| Authorized Official | DEFURIO, ANTHONY (EXECUTIVE VICE PRESIDENT/CFO) |
| NPI Enumeration Date | 10/02/2018 |
Other providers sharing the same authorized official: DEFURIO, ANTHONY
| Year | Claims | Total Paid |
|---|---|---|
| 2019 | 24,674 | $1.14M |
| 2020 | 18,792 | $1.03M |
| 2021 | 19,522 | $1.41M |
| 2022 | 19,379 | $1.89M |
| 2023 | 22,825 | $2.23M |
| 2024 | 20,323 | $2.07M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 14,330 | 13,206 | $4.31M |
| 99284 | Emergency department visit for the evaluation and management, high severity | 11,248 | 10,379 | $3.03M |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4,438 | 4,104 | $982K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 2,465 | 2,245 | $350K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 12,779 | 11,322 | $183K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3,380 | 3,089 | $125K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1,502 | 1,342 | $121K |
| 80053 | Comprehensive metabolic panel | 11,353 | 10,470 | $86K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 12,028 | 10,989 | $80K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2,953 | 2,773 | $60K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 844 | 768 | $56K |
| 71045 | Radiologic examination, chest; single view | 1,558 | 1,437 | $47K |
| J3490 | Unclassified drugs | 11,041 | 5,714 | $35K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1,082 | 944 | $29K |
| Q3014 | Telehealth originating site facility fee | 1,965 | 1,826 | $26K |
| 80061 | Lipid panel | 2,238 | 2,100 | $24K |
| 83036 | Hemoglobin; glycosylated (A1C) | 2,432 | 2,282 | $19K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1,236 | 1,088 | $17K |
| 71046 | Radiologic examination, chest; 2 views | 397 | 372 | $15K |
| 84484 | 1,877 | 1,617 | $13K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 182 | 155 | $10K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 25 | 25 | $10K |
| 81025 | 1,262 | 1,172 | $10K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 461 | 429 | $10K |
| 70450 | Computed tomography, head or brain; without contrast material | 55 | 50 | $8K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1,280 | 1,158 | $8K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 36 | 31 | $7K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1,243 | 1,112 | $7K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 5,099 | 2,669 | $7K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 136 | 113 | $5K |
| 80048 | Basic metabolic panel (calcium, ionized) | 799 | 737 | $5K |
| G0378 | Hospital observation service, per hour | 26 | 26 | $5K |
| 81001 | 1,488 | 1,400 | $5K | |
| 84443 | Thyroid stimulating hormone (TSH) | 363 | 338 | $4K |
| 36415 | Collection of venous blood by venipuncture | 2,223 | 2,091 | $4K |
| 85027 | 984 | 931 | $4K | |
| 96361 | Intravenous infusion, hydration; each additional hour | 619 | 549 | $4K |
| 87430 | 245 | 227 | $4K | |
| 83735 | 736 | 672 | $4K | |
| 84466 | 348 | 316 | $3K | |
| 82728 | 310 | 278 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 1,326 | 1,235 | $3K |
| 96127 | 1,535 | 1,444 | $3K | |
| 83690 | 407 | 383 | $3K | |
| 87070 | 171 | 163 | $2K | |
| 80050 | General health panel | 47 | 40 | $2K |
| 82607 | 172 | 162 | $2K | |
| 83540 | 348 | 316 | $2K | |
| 85610 | 483 | 451 | $1K | |
| 87486 | 36 | 31 | $1K | |
| 87581 | 36 | 31 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 200 | 175 | $933.29 |
| 81003 | 398 | 378 | $895.86 | |
| 84481 | 65 | 56 | $875.04 | |
| 82803 | 40 | 39 | $687.19 | |
| 83880 | 27 | 26 | $672.92 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 37 | 36 | $647.93 |
| 86803 | 43 | 38 | $630.07 | |
| 80143 | 17 | 13 | $550.14 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 25 | 25 | $429.56 |
| 80179 | 17 | 13 | $409.39 | |
| 87522 | Neg quan hep c or qual rna | 19 | 14 | $382.23 |
| 83605 | 53 | 51 | $335.32 | |
| 82043 | 75 | 74 | $334.65 | |
| 82570 | 75 | 74 | $299.35 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 14 | 14 | $230.53 |
| 84439 | 39 | 38 | $224.80 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 85 | 80 | $221.42 |
| 87086 | Culture, bacterial; quantitative colony count, urine | 27 | 25 | $202.01 |
| 86702 | 14 | 12 | $144.77 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 12 | 12 | $134.64 |
| 87081 | 12 | 12 | $117.92 | |
| 90686 | 64 | 64 | $115.76 | |
| 86701 | 14 | 12 | $109.31 | |
| 82746 | 13 | 13 | $75.50 | |
| 81002 | 27 | 27 | $46.90 | |
| 82962 | 30 | 24 | $27.40 | |
| 81000 | 12 | 12 | $20.75 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 27 | 26 | $5.39 |
| J8597 | Antiemetic drug, oral, not otherwise specified | 13 | 13 | $4.80 |
| A9270 | Non-covered item or service | 394 | 214 | $0.00 |